Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
SARC-F is a quick questionnaire-based screening tool for sarcopenia risk in older adults and medically complex populations. A score of 4 or higher commonly indicates likely sarcopenia risk and supports further evaluation of muscle strength and performance.
Formula: SARC-F = sum of 5 items scored 0-2 each; total range 0-10.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
SARC-F is an interviewer-administered or self-completed 5-item questionnaire. The five items with their response options are: (1) Strength — 'How much difficulty do you have in lifting and carrying 10 pounds (4.5 kg)?' Response: None (0), Some difficulty (1), A lot of difficulty or unable (2). (2) Assistance in walking — 'How much difficulty do you have walking across a room?' Response: None (0), Some difficulty (1), A lot of difficulty, use aids, or unable without help (2). (3) Rise from a chair — 'How much difficulty do you have transferring from a chair or bed?' Response: None (0), Some difficulty (1), A lot of difficulty or unable without help (2). (4) Climb stairs — 'How much difficulty do you have climbing a flight of 10 stairs?' Response: None (0), Some difficulty (1), A lot of difficulty or unable (2). (5) Falls — 'How many times have you fallen in the past year?' Response: None (0), 1–3 falls (1), 4 or more falls (2). The SARC-F can be self-completed in approximately 1–2 minutes, making it suitable for waiting room pre-screening, outpatient clinic administration, or completion by community health workers.
Add the responses from all five SARC-F items. Each item is scored 0, 1, or 2, for a total score range of 0–10. A score of 0 indicates no self-reported functional limitation across strength, walking, chair transfer, stair climbing, or falls — very low probability of clinically significant sarcopenia. A score of 1–3 indicates some self-reported limitations but falls below the positive screen threshold — note individual items with scores of 1–2 as these may warrant monitoring. A score of 4 or above is the standard threshold for a positive SARC-F screen, indicating probable sarcopenia risk and warranting confirmatory objective assessment. Higher scores within the positive range (e.g., 7–10) indicate more severe functional limitation and higher likelihood of confirmed sarcopenia with muscle strength and performance deficits.
SARC-F score interpretation: 0–3 = Screen negative. Low probability of sarcopenia. In community-dwelling older adults over 65, repeat SARC-F screening annually or at clinical visits with any functional change. 4–10 = Screen positive. Probable sarcopenia risk. Proceed to confirmatory objective assessments per EWGSOP2 (European Working Group on Sarcopenia in Older People) diagnostic algorithm: (1) Muscle strength measurement — handgrip dynamometry (low strength: <27 kg men, <16 kg women) or 5-times sit-to-stand test (<12 seconds) as alternative. Low strength confirms 'probable sarcopenia' warranting intervention. (2) If strength is low: muscle quantity/quality assessment — DXA (appendicular lean mass index <7.0 kg/m² men, <5.5 kg/m² women) or BIA for body composition. (3) Physical performance — gait speed (≤0.8 m/s), [SPPB ≤8](/tools/sppb-score), or TUG ≥20 seconds. Low strength + low quantity = sarcopenia; add low performance = severe sarcopenia. Document SARC-F score, positive screen, and referral for objective evaluation in the clinical record.
Primary care physicians, geriatricians, nurse practitioners, physician assistants
Sarcopenia affects an estimated 10–16% of community-dwelling adults over 65 and up to 50% of those over 80. SARC-F is endorsed by EWGSOP2 (2019), AWGS (Asian Working Group for Sarcopenia 2019), and multiple geriatric medicine societies as the preferred initial screening tool for sarcopenia in primary care settings due to its speed (1–2 minutes), no equipment requirement, and validated positive screen cutoff (≥4). Annual SARC-F screening for all patients ≥65 during wellness visits identifies those needing confirmatory assessment. Positive screen triggers objective evaluation: handgrip strength, BIA or DXA, and gait speed. Earlier sarcopenia identification enables initiation of evidence-based interventions (resistance training, protein optimization) before severe disability develops.
Surgeons, anesthesiologists, geriatric surgery programs, perioperative nurses
Pre-operative sarcopenia (diagnosed or screened by SARC-F) is an independent predictor of post-operative complications, prolonged hospital length of stay, non-home discharge, and mortality in patients undergoing major elective surgery (colorectal, oncological, cardiovascular, orthopedic). SARC-F ≥4 before surgery identifies patients who benefit from pre-operative prehabilitation: structured resistance exercise and protein supplementation in the 4–8 weeks before surgery to improve muscle function and reduce surgical risk. Multiple enhanced recovery after surgery (ERAS) protocols for patients aged ≥65 include pre-operative sarcopenia screening as part of comprehensive geriatric assessment. SARC-F is practical in busy pre-assessment clinics due to its brief administration.
Oncologists, hepatologists, cardiologists, pulmonologists, rheumatologists
Sarcopenia is prevalent in and prognostically important across multiple chronic disease conditions: liver cirrhosis (sarcopenia predicts decompensation and transplant outcomes), COPD (muscle wasting predicts exacerbation frequency and mortality), heart failure (cardiac cachexia), cancer (cachexia predicts chemotherapy toxicity and survival), and rheumatoid arthritis (inflammatory sarcopenia). SARC-F provides a quick, disease-agnostic screening tool that can be integrated into routine clinic follow-up visits for these patient populations. Positive SARC-F in these settings triggers specialist nutrition consultation, disease-specific rehabilitation referral, and consideration of sarcopenia in treatment planning (e.g., dose adjustment for chemotherapy agents with muscle wasting side effects).
Geriatric oncologists, oncology nurses, cancer care coordinators
Sarcopenia assessed by SARC-F or objective measures is one of the strongest predictors of chemotherapy toxicity, functional decline, and survival in older adults with cancer. The International Society of Geriatric Oncology (SIOG) recommends comprehensive geriatric assessment (CGA) — which includes sarcopenia screening — for all older adults before initiating cancer treatment. SARC-F ≥4 in cancer patients identifies those needing: oncologic rehabilitation referral, protein and caloric supplementation to prevent further muscle loss during treatment, individualized chemotherapy dosing, dose-reduction planning for neurotoxic agents, and advanced care planning discussion. Serial SARC-F monitoring during cancer treatment tracks functional trajectory.
Physiotherapists, falls prevention nurses, occupational therapists
Sarcopenia and falls risk are tightly linked — reduced muscle strength and mass directly impair postural stability and recovery from perturbations. SARC-F item 5 (falls) scores recent fall history, and a positive SARC-F screen often co-occurs with elevated [TUG](/tools/get-up-and-go), [SPPB](/tools/sppb-score), and [Morse Fall Scale](/tools/morse-fall-scale) scores. In falls prevention clinics and physiotherapy assessment, SARC-F provides a structured screening question set that covers multiple fall-relevant functional domains (strength, walking, chair transfer, stair climbing, fall history) in one tool. SARC-F results guide physical therapy goal-setting: patients scoring high on specific items (e.g., Strength=2, Rise from Chair=2) have resistance training targets directly mapped to their functional deficits.
A SARC-F score ≥4 indicates probable sarcopenia risk and triggers objective confirmatory assessment — it does not diagnose sarcopenia. The EWGSOP2 diagnostic algorithm requires low muscle strength (handgrip or chair stand) and/or low muscle quantity (DXA or BIA) to confirm the diagnosis. Do not label a patient as 'sarcopenic' and initiate formal interventions based on SARC-F alone. The screen is a gateway to efficient identification of who needs confirmatory testing, not a standalone diagnostic criterion.
SARC-F has specificity of approximately 70–90% (few false positives) but sensitivity of only approximately 20–60% (many false negatives, particularly in early sarcopenia). This means SARC-F is good at confirming probable sarcopenia risk when positive, but a negative score does not rule out sarcopenia in patients with objective evidence of muscle weakness or wasting. For patients with clinical concern (unexplained weight loss, observed weakness, functional decline) despite SARC-F score below 4, proceed directly to objective strength testing (handgrip) — do not rely on the negative SARC-F screen alone.
SARC-F item 5 (falls in the past year: 0 = none, 1 = 1–3 falls, 2 = 4+ falls) correlates strongly with ongoing fall risk independent of the total SARC-F score. Any patient who scores 2 on item 5 (4 or more falls in the past year) warrants a comprehensive multifactorial falls assessment regardless of their total SARC-F score. The USPSTF and AGS/BGS guidelines both recommend intervention for older adults with 2+ falls in the past year or any fall with injury. Use the falls item as a fall risk flag alongside its contribution to the sarcopenia screen.
The EWGSOP2-recommended rapid sarcopenia identification pathway is SARC-F screening (≥4) followed by grip strength measurement. The combination of SARC-F ≥4 plus low handgrip strength (<27 kg men, <16 kg women) has significantly higher positive predictive value for confirmed sarcopenia than either measure alone. A portable hand dynamometer is inexpensive (<$100), quick to use (30-second test), and can be deployed in primary care or clinic settings. If a dynamometer is not available, the 5-times sit-to-stand test (<12 seconds for 5 repetitions = adequate strength) is a validated alternative performance-based measure.
Positive SARC-F screen should trigger referral for structured resistance training — this is the intervention with the most robust evidence for reversing muscle weakness and improving physical function in sarcopenia. Recommended: 2–3 sessions per week of progressive resistance training targeting all major muscle groups (leg press, seated row, chest press, hip extension); target load ≥70% of 1-repetition maximum for optimal muscle protein synthesis stimulus. Even in frail older adults, appropriately supervised progressive resistance training is safe and effective. Protein optimization (≥1.2 g/kg/day, with leucine-rich protein sources) is the essential nutritional adjunct — protein without exercise is less effective than the combination.
Inadequate dietary protein is a major driver of sarcopenia progression. Current PROT-AGE guidelines recommend protein intake ≥1.0–1.2 g/kg/day for older adults to maintain muscle mass, increasing to 1.2–1.5 g/kg/day for those with sarcopenia risk and ≥1.5 g/kg/day in those with active chronic disease or injury. Leucine-enriched whey protein supplements taken within 30 minutes after resistance exercise maximize muscle protein synthesis signaling. Essential amino acid supplementation may be helpful for patients with very low dietary protein intake. A positive SARC-F screen should trigger dietary assessment and dietitian referral for protein optimization.
SARC-F has been validated in multiple ethnic groups including European, East Asian (Chinese, Japanese, Korean), South Asian, and Latin American populations. The positive screen threshold of ≥4 performs comparably across these groups, making SARC-F one of the few geriatric screening tools that does not require population-specific cutoff recalibration. However, the criterion thresholds for objective confirmation (handgrip, appendicular lean mass) DO differ by sex and ethnicity — use EWGSOP2 thresholds for European populations and AWGS2 thresholds for Asian populations.
Vitamin D receptors are expressed in skeletal muscle, and vitamin D deficiency (25-hydroxyvitamin D <50 nmol/L) is associated with muscle weakness, impaired muscle fiber composition, and increased fall risk. Correction of vitamin D deficiency (target 25-OHD >75 nmol/L) has modest benefit for muscle function and fall prevention in deficient older adults. Check vitamin D status (25-hydroxyvitamin D) in all patients with positive SARC-F screen and supplement if deficient: 1,000–2,000 IU/day vitamin D3 to reach and maintain adequacy. Vitamin D supplementation alone (without exercise) has limited effect on muscle mass — it should be part of a multimodal intervention.
SARC-F developed and validated by Malmström TK and Morley JE (J Am Med Dir Assoc 2013) in a primary care older adult population. Validation meta-analysis: Ida S et al. (J Am Med Dir Assoc 2018) — pooled sensitivity 21%, specificity 90%, AUC 0.74 vs. EWGSOP1 criteria. AWGS 2019 endorsement: Chen LK et al. (J Am Med Dir Assoc 2020). EWGSOP2 recommendation: Cruz-Jentoft AJ et al. (Age Ageing 2019). SARC-CalF: Barbosa-Silva TG et al. (J Am Med Dir Assoc 2016). Resistance training in sarcopenia: Peterson MD et al. (Am J Med 2011) — meta-analysis showing significant strength gains with resistance training in older adults.
Higher SARC-F scores indicate greater probable sarcopenia risk and functional vulnerability.
Use for rapid sarcopenia risk screening in outpatient geriatrics, primary care, rehabilitation, and preoperative assessments.
SARC-F may have limited sensitivity in early sarcopenia and should be complemented by physical performance and strength testing.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Assess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.
OpenGeriatricsAssess independence in six basic activities of daily living with the Katz ADL Index. Scores range from 0 (dependent) to 6 (fully independent).
OpenGeriatricsAssess independence in core activities of daily living with the Barthel Index (0-100), commonly used in rehabilitation and geriatric care.
OpenGeriatricsAssess mobility and fall risk with the Timed Up and Go (TUG) test. TUG >12 seconds indicates high fall risk. Times the performance of standing, walking 3 meters, turning, and returning to seated.
Open